MX344596B - Vacuna de subunidad recombinante del virus del dengue. - Google Patents
Vacuna de subunidad recombinante del virus del dengue.Info
- Publication number
- MX344596B MX344596B MX2013004741A MX2013004741A MX344596B MX 344596 B MX344596 B MX 344596B MX 2013004741 A MX2013004741 A MX 2013004741A MX 2013004741 A MX2013004741 A MX 2013004741A MX 344596 B MX344596 B MX 344596B
- Authority
- MX
- Mexico
- Prior art keywords
- dengue virus
- compositions
- den4
- present
- virus vaccine
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 230000028993 immune response Effects 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 235000004252 protein component Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40831010P | 2010-10-29 | 2010-10-29 | |
| PCT/US2011/058026 WO2012154202A1 (en) | 2010-10-29 | 2011-10-27 | Recombinant subunit dengue virus vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004741A MX2013004741A (es) | 2013-06-05 |
| MX344596B true MX344596B (es) | 2016-12-20 |
Family
ID=47139466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004741A MX344596B (es) | 2010-10-29 | 2011-10-27 | Vacuna de subunidad recombinante del virus del dengue. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9198964B2 (https=) |
| EP (1) | EP2632485A4 (https=) |
| JP (1) | JP6018575B2 (https=) |
| KR (1) | KR20130138789A (https=) |
| AU (1) | AU2011367817B2 (https=) |
| BR (1) | BR112013009649A2 (https=) |
| MX (1) | MX344596B (https=) |
| MY (1) | MY166534A (https=) |
| SG (3) | SG10201508700XA (https=) |
| WO (1) | WO2012154202A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011119628A2 (en) | 2010-03-23 | 2011-09-29 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2011367817B2 (en) | 2010-10-29 | 2015-05-28 | Merck Sharp & Dohme Corp. | Recombinant subunit dengue virus vaccine |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2016523251A (ja) * | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| GB201413086D0 (en) | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
| ES2981476T3 (es) * | 2014-12-22 | 2024-10-09 | Merck Sharp & Dohme Llc | Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas |
| US11241491B2 (en) | 2017-05-23 | 2022-02-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus serotype 4 epitopes |
| WO2019112921A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| CA3086456A1 (en) | 2017-12-21 | 2019-06-27 | Kirin Holdings Kabushiki Kaisha | Cross-immunizing antigen vaccine and method for preparation thereof |
| WO2019162423A1 (en) * | 2018-02-22 | 2019-08-29 | Sanofi-Aventis Deutschland Gmbh | Variants of porcine trypsin |
| AU2019322828A1 (en) * | 2018-08-14 | 2021-02-25 | Merck Sharp & Dohme Llc | A virus neutralization assay utilizing imaging cytometry |
| KR102301130B1 (ko) * | 2018-12-27 | 2021-09-15 | 주식회사 이뮨메드 | 뎅기출혈열 진단 키트 |
| EP4284426A1 (en) * | 2021-01-28 | 2023-12-06 | Vaccinvent GmbH | Method and means for modulating b-cell mediated immune responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136561A (en) | 1995-05-24 | 2000-10-24 | Hawaii Biotechnology Group, Inc. | Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems |
| DE69624815T2 (de) * | 1995-05-24 | 2003-07-10 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
| WO1999006068A2 (en) * | 1997-07-31 | 1999-02-11 | Hawaii Biotechnology Group, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
| US6416763B1 (en) | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
| US6432411B1 (en) * | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| CU23245A1 (es) | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
| WO2004052293A2 (en) * | 2002-12-11 | 2004-06-24 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| US20110262472A1 (en) | 2008-04-22 | 2011-10-27 | Cytos Biotechnology Ag | Vaccine compositions for the treatment of dengue fever and uses thereof |
| AU2011367817B2 (en) | 2010-10-29 | 2015-05-28 | Merck Sharp & Dohme Corp. | Recombinant subunit dengue virus vaccine |
-
2011
- 2011-10-27 AU AU2011367817A patent/AU2011367817B2/en not_active Ceased
- 2011-10-27 US US13/881,423 patent/US9198964B2/en active Active
- 2011-10-27 SG SG10201508700XA patent/SG10201508700XA/en unknown
- 2011-10-27 MX MX2013004741A patent/MX344596B/es active IP Right Grant
- 2011-10-27 MY MYPI2013001004A patent/MY166534A/en unknown
- 2011-10-27 EP EP11865332.8A patent/EP2632485A4/en not_active Withdrawn
- 2011-10-27 JP JP2013536813A patent/JP6018575B2/ja not_active Expired - Fee Related
- 2011-10-27 SG SG2013021167A patent/SG189048A1/en unknown
- 2011-10-27 SG SG10201801947YA patent/SG10201801947YA/en unknown
- 2011-10-27 BR BR112013009649A patent/BR112013009649A2/pt not_active Application Discontinuation
- 2011-10-27 WO PCT/US2011/058026 patent/WO2012154202A1/en not_active Ceased
- 2011-10-27 KR KR1020137010730A patent/KR20130138789A/ko not_active Withdrawn
-
2015
- 2015-09-22 US US14/861,425 patent/US10137187B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013542224A (ja) | 2013-11-21 |
| CN103179983A (zh) | 2013-06-26 |
| MX2013004741A (es) | 2013-06-05 |
| AU2011367817B2 (en) | 2015-05-28 |
| JP6018575B2 (ja) | 2016-11-02 |
| AU2011367817A1 (en) | 2013-04-18 |
| BR112013009649A2 (pt) | 2016-07-12 |
| MY166534A (en) | 2018-07-10 |
| US9198964B2 (en) | 2015-12-01 |
| SG10201508700XA (en) | 2015-11-27 |
| KR20130138789A (ko) | 2013-12-19 |
| WO2012154202A1 (en) | 2012-11-15 |
| US20160074502A1 (en) | 2016-03-17 |
| US20130216575A1 (en) | 2013-08-22 |
| EP2632485A4 (en) | 2014-05-28 |
| US10137187B2 (en) | 2018-11-27 |
| SG10201801947YA (en) | 2018-04-27 |
| EP2632485A1 (en) | 2013-09-04 |
| SG189048A1 (en) | 2013-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX344596B (es) | Vacuna de subunidad recombinante del virus del dengue. | |
| JP2013542224A5 (https=) | ||
| Ip et al. | Therapeutic vaccination against chronic hepatitis C virus infection | |
| HUE055070T2 (hu) | Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra | |
| PH12018502403A1 (en) | Hiv vaccine formulation | |
| MX341775B (es) | Vectores para vacunas y metodos para potenciar respuestas inmunes. | |
| WO2010141084A3 (en) | Recombinant subunit west nile virus vaccine for protections of human subjects | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| JP2016508999A5 (https=) | ||
| KR20260047600A (ko) | 어쥬번트로서 인터류킨-33을 갖는 백신 | |
| PH12015502844B1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| RU2013147745A (ru) | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей | |
| IL182440A0 (en) | Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection | |
| Chromova et al. | Effect of influenza vaccines on subpopulations of blood dendritic cells | |
| WO2012073257A3 (en) | Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
| RU2008114841A (ru) | Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса | |
| PH12022552300A1 (en) | Cpg-adjuvanted sars-cov-2 virus vaccine | |
| PH12022552239A1 (en) | INACTIVATED SARS-CoV-2 VIRUS VACCINE | |
| JP2016514114A5 (https=) | ||
| PH12014502085A1 (en) | Modified marek`s disease virus, and vaccines made therefrom | |
| IL208862A (en) | Use of a protein capable of eliciting an immune response against tat protein to prepare a drug for the prevention or treatment of AIDS (aids) in the patient and the preparations and vaccines associated with this use | |
| Dawar et al. | Current status of the coronavirus vaccination development: a review | |
| Polovinkina et al. | Structure and adjuvanticity immune properties of muramyldipeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |